Annual Cash & Cash Equivalents
$23.39 M
+$6.00 M+34.46%
30 September 2023
Summary:
Outlook Therapeutics annual cash & cash equivalents is currently $23.39 million, with the most recent change of +$6.00 million (+34.46%) on 30 September 2023. During the last 3 years, it has risen by +$8.91 million (+61.58%). OTLK annual cash & cash equivalents is now at all-time high.OTLK Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$32.02 M
-$15.20 M-32.19%
30 June 2024
Summary:
Outlook Therapeutics quarterly cash and cash equivalents is currently $32.02 million, with the most recent change of -$15.20 million (-32.19%) on 30 June 2024. Over the past year, it has increased by +$8.63 million (+36.90%). OTLK quarterly cash and cash equivalents is now -54.35% below its all-time high of $70.15 million, reached on 31 December 2021.OTLK Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
OTLK Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | +36.9% |
| 3 y3 years | +61.6% | +121.2% |
| 5 y5 years | +191.8% | +299.5% |
OTLK Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +61.6% | -54.4% | +209.2% |
| 5 y | 5 years | at high | +191.8% | -54.4% | +2301.3% |
| alltime | all time | at high | +1262.1% | -54.4% | >+9999.0% |
Outlook Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| June 2024 | - | $32.02 M(-32.2%) |
| Mar 2024 | - | $47.23 M(+356.0%) |
| Dec 2023 | - | $10.36 M(-55.7%) |
| Sept 2023 | $23.39 M(+34.5%) | $23.39 M(-30.6%) |
| June 2023 | - | $33.71 M(-22.7%) |
| Mar 2023 | - | $43.63 M(-16.6%) |
| Dec 2022 | - | $52.34 M(+200.9%) |
| Sept 2022 | $17.40 M(+20.2%) | $17.40 M(-33.1%) |
| June 2022 | - | $26.02 M(-55.5%) |
| Mar 2022 | - | $58.42 M(-16.7%) |
| Dec 2021 | - | $70.15 M(+384.6%) |
| Sept 2021 | $14.48 M(+15.5%) | $14.48 M(-26.5%) |
| June 2021 | - | $19.69 M(-47.0%) |
| Mar 2021 | - | $37.17 M(+567.5%) |
| Dec 2020 | - | $5.57 M(-55.6%) |
| Sept 2020 | $12.54 M | $12.54 M(-47.7%) |
| June 2020 | - | $23.95 M(+414.8%) |
| Mar 2020 | - | $4.65 M(+248.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2019 | - | $1.33 M(-83.4%) |
| Sept 2019 | $8.02 M(+366.7%) | $8.02 M(-42.9%) |
| June 2019 | - | $14.03 M(+8920.5%) |
| Mar 2019 | - | $155.50 K(-31.7%) |
| Dec 2018 | - | $227.70 K(-86.7%) |
| Sept 2018 | $1.72 M(-46.1%) | $1.72 M(-85.4%) |
| June 2018 | - | $11.80 M(+98.7%) |
| Mar 2018 | - | $5.94 M(-57.1%) |
| Dec 2017 | - | $13.84 M(+334.4%) |
| Sept 2017 | $3.19 M(+35.4%) | $3.19 M(+2177.0%) |
| June 2017 | - | $139.90 K(+72.7%) |
| Mar 2017 | - | $81.00 K(-96.1%) |
| Dec 2016 | - | $2.08 M(-11.6%) |
| Sept 2016 | $2.35 M(-74.1%) | $2.35 M(-82.6%) |
| June 2016 | - | $13.56 M(+376.9%) |
| Mar 2016 | - | $2.84 M(-73.7%) |
| Dec 2015 | - | $10.81 M(+19.1%) |
| Sept 2015 | $9.07 M(0.0%) | $9.07 M |
| Sept 2014 | $9.07 M | - |
FAQ
- What is Outlook Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Outlook Therapeutics?
- What is Outlook Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Outlook Therapeutics?
- What is Outlook Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Outlook Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of OTLK is $23.39 M
What is the all time high annual cash & cash equivalents for Outlook Therapeutics?
Outlook Therapeutics all-time high annual cash & cash equivalents is $23.39 M
What is Outlook Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of OTLK is $32.02 M
What is the all time high quarterly cash and cash equivalents for Outlook Therapeutics?
Outlook Therapeutics all-time high quarterly cash and cash equivalents is $70.15 M
What is Outlook Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, OTLK quarterly cash and cash equivalents has changed by +$8.63 M (+36.90%)